September 12, 2014
An interesting roundtable discussion by prominent professionals focused on the rise of personalized medicine and its potential impact on a variety of diseases. Participants in this roundtable sponsored by the House Energy and Commerce Committee include industry, medical, FDA and congressional leadership.
The roundtable explores how genomic sequencing and diagnostic testing as well as regulations affect innovative product development and delivery. A number of comments focused on education of scientists, physicians and patients. Funding, collaboration and data sharing are also critical.
Dr. Franklin Cockerill, MD, chair of the Mayo Clinic Department of Laboratory Medicine and Pathology participated in this roundtable. He emphasized the importance of providing government funding for research, regulatory bodies, clinical validation, patient safety and encouraging innovation. Mayo Clinic is a leader in genomics and is currently conducting research on the relationship of SCAD and genetics.